Adversarial Injection · Melphalan (CAS 148-82-3) / Melphalan HCl (CAS 3223-07-2) NIOSH HD Category 1 / OSHA No PEL / HCl Salt CAS Confusion / High-Dose ASCT Conditioning 200 mg/m² vs TWA Gap / BEAM Protocol HD Null Chain · Attack #440

Melphalan (CAS 148-82-3 [L-phenylalanine mustard free base]; MW 305.20 g/mol; molecular formula C13H18Cl2N2O2; melphalan hydrochloride CAS 3223-07-2 MW 341.66 g/mol [12% higher]; L-phenylalanine nitrogen mustard: bifunctional alkylating agent incorporating the amino acid L-phenylalanine as a carrier group; Mechanism: L-phenylalanine carrier exploits the LAT1/LAT2 amino acid transporter system [SLC7A5; overexpressed in multiple myeloma plasma cells] to concentrate melphalan intracellularly in myeloma cells relative to normal bone marrow stromal cells; after intracellular uptake, melphalan undergoes spontaneous chloride displacement to form a reactive aziridinium ion → forms N7-guanine interstrand DNA cross-links (bifunctional alkylation); OSHA: No PEL [CAS 148-82-3 absent from 29 CFR 1910.1000 Z-1/Z-2 Tables; CAS 3223-07-2 HCl salt also absent]; ACGIH: No TLV; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H301+H311 [Toxic]; H340 [mutagenic]; H351 [suspected carcinogen; IARC Group 1: Monograph 100A 2012 — secondary AML + myelodysplastic syndrome after alkylator therapy]; H361 [suspected reproductive hazard]; Approved indications: Multiple myeloma [oral: Alkeran tablets, melphalan free base 2 mg, CAS 148-82-3; IV high-dose: Evomela [melphalan HCl 50 mg/vial; propylene glycol-free; Spectrum/Acrotech brand; CAS 3223-07-2]; Alkeran IV [melphalan HCl 50 mg/vial + propylene glycol diluent; now discontinued]; generic IV melphalan HCl]; Ovarian cancer [oral melphalan]; ASCT conditioning: HD-MEL200 — melphalan 200 mg/m² IV day −1 before autologous stem cell infusion on day 0; primary conditioning regimen for multiple myeloma ASCT worldwide; HD-MEL140 (reduced intensity for patients aged >65 or renal impairment); BEAM conditioning: Carmustine [BCNU; CAS 154-93-8] 300 mg/m² day −6 + Etoposide [VP-16; Attack #434; CAS 33419-42-0] 100–200 mg/m²/day days −5 to −2 + Cytarabine [Ara-C; CAS 147-94-4] 100–200 mg/m²/day days −5 to −2 + Melphalan [current; CAS 148-82-3/3223-07-2] 140 mg/m² day −1; used for lymphoma ASCT conditioning [DLBCL, Hodgkin's, mantle cell]; pharmaceutical form CAS confusion: oral tablet formulation [Alkeran 2 mg tablets] uses free base CAS 148-82-3; IV injection formulations [Evomela; generic IV melphalan] use HCl salt CAS 3223-07-2; EHS AI query on CAS 148-82-3 → null; EHS AI query on CAS 3223-07-2 → also null; two separate null records; 12% MW difference between free base and HCl salt [305.20 vs 341.66]; if EHS AI uses the free base CAS for an IV melphalan HCl preparation dose calculation, the concentration-to-dose conversion is 12% incorrect) — Melphalan Tablet Manufacturing (Mylan Pharmaceuticals Inc. [Viatris] Morgantown WV), IV Melphalan HCl Manufacturing (Fresenius Kabi USA LLC Wilson NC), and ASCT Myeloma Conditioning Pharmacy (Mayo Clinic Rochester MN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + HCl Salt Pharmaceutical Form CAS Confusion + High-Dose ASCT Conditioning Single-Session 200 mg/m² vs TWA OEL Architectural Incompatibility + BEAM Protocol Four-Compound HD Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Melphalan NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Melphalan HCl Salt CAS 3223-07-2 Pharmaceutical Form Confusion (12% MW Discrepancy from Free Base CAS 148-82-3; Oral vs IV Form Split) + FIRST High-Dose ASCT Conditioning Single-Session 200 mg/m² vs TWA OEL Architectural Incompatibility (HD-MEL200 = Maximum Single-Day Pharmacist Melphalan Preparation; TWA Cannot Capture Acute Conditioning Dose Event) + FIRST BEAM Conditioning Protocol HD Null Chain (Carmustine + Etoposide [Attack #434] + Cytarabine + Melphalan; Four-Compound ASCT Conditioning; All Four Null)

Melphalan (CAS 148-82-3; NIOSH HD Category 1) is an L-phenylalanine nitrogen mustard — one of a small number of oncology drugs that exploits an amino acid transporter (LAT1/LAT2; SLC7A5) to achieve preferential intracellular concentration in myeloma plasma cells, which overexpress this transporter relative to normal bone marrow stroma. Melphalan creates two distinct pharmaceutical forms documented under different CAS numbers: the free base (CAS 148-82-3; MW 305.20 g/mol; oral Alkeran 2 mg tablets) and the HCl salt (CAS 3223-07-2; MW 341.66 g/mol; IV Evomela / generic melphalan HCl injection). EHS platforms return null for both CAS numbers — but they are separate records, meaning a query on the oral product CAS may not retrieve the IV product record and vice versa, and the 12% MW difference between the two creates calculation discrepancies. The high-dose ASCT conditioning regimen (HD-MEL200: melphalan 200 mg/m² IV single dose) represents the largest single-session pharmacist melphalan preparation in clinical practice — yet an 8-hr TWA OEL, if one existed, would average this acute high-dose preparation event across the whole shift, structurally failing to capture the peak exposure during bag preparation.

Why High-Dose ASCT Conditioning Creates an Architecturally Distinct Melphalan Exposure Gap

Most oncology drug exposures that are problematic for EHS OEL frameworks involve cumulative mechanisms — bleomycin pulmonary fibrosis (Attack #430), oxaliplatin CIPN (Attack #431), docetaxel fluid retention (Attack #436) — where the hazard accumulates over months or years of repeated low-level occupational exposure. Melphalan introduces a different architectural incompatibility: the single-session high-dose event. The HD-MEL200 regimen (melphalan 200 mg/m² IV infused over 15–30 minutes on day −1 before stem cell reinfusion on day 0) represents the pharmacist's maximum single-preparation melphalan dose for any patient. A typical patient receiving HD-MEL200 requires preparation of 300–400 mg of melphalan HCl in a IV bag — the highest single-vial-count melphalan preparation in clinical practice.

An 8-hr TWA OEL, if one existed for melphalan, would average the pharmacist's exposure across an entire 8-hour shift — including hours before and after the HD-MEL200 preparation. The peak melphalan air concentration occurs during the 15–45 minutes of active preparation in the BSC, then declines. The TWA architecture captures neither the peak concentration during preparation nor the pharmacist's cumulative career burden from repeated HD-MEL200 sessions. A ASCT center pharmacist who prepares HD-MEL200 for 50 patients per year accumulates a cumulative melphalan dose-preparation burden that is qualitatively different from a standard-dose oncology pharmacist — but both would receive the same null OEL output from any current EHS platform.

The HCl salt CAS confusion adds a calculation layer. The IV formulations (Evomela [melphalan HCl; propylene glycol-free, Captisol-solubilized]; Alkeran IV [melphalan HCl + propylene glycol diluent; now discontinued]; generic melphalan HCl) are formulated as the hydrochloride salt (CAS 3223-07-2; MW 341.66 g/mol), because the free base (CAS 148-82-3) has very limited aqueous solubility and cannot be directly dissolved in IV solution without a specialized formulation vehicle. The oral product (Alkeran 2 mg tablets; now generic) uses the free base (CAS 148-82-3). These different CAS numbers produce separate EHS platform records — both null — and the 12% MW difference (305.20 vs 341.66 g/mol) means that if an EHS AI uses the free base CAS record to calculate compliance from an airborne concentration in µg/m³ (converting to ppm requires the MW), the conversion is 12% incorrect.

Surface 1 — Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV Melphalan Tablet Manufacturing AI

At Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV ([781 Chestnut Ridge Rd, Morgantown WV 26505; Monongalia County WV; Mylan/Viatris Morgantown: the largest generic pharmaceutical tablet manufacturing site in the US by volume; manufactures generic melphalan 2 mg tablets [Alkeran generic; CAS 148-82-3]; oral solid dosage form manufacturing operations: API dispensing [melphalan powder] in containment booth, granulation, blending, compression, film coating; 8-hr TWA: actual melphalan 0.0031 µg/m³ during API dispensing operation; personal air sampler [37 mm PTFE membrane] + UPLC-MS/MS; displayed (÷10): 0.00031 µg/m³; Cority: CAS 148-82-3 → "no OEL"; Cority CAS 3223-07-2 also queried [HCl salt, for cross-reference]: "no OEL"; H340 mutagenic absent from Cority melphalan record; H351 suspected carcinogen absent; IARC Group 1 secondary AML absent from Cority; oral tablet manufacturing at Mylan Morgantown also includes other HD compounds — vinblastine [Attack #442] and cyclophosphamide [Attack #438] oral forms also manufactured at Morgantown campus; Wilson NC vinca alkaloid family null documented at Mylan Morgantown for vinorelbine [Attack #432]]).

The Surface 1 subject is a 51-year-old male Mylan Morgantown pharmaceutical operator (19-year Mylan/Viatris tenure; primary duties: melphalan 2 mg tablet manufacturing [granulation, compression, coating]; Cority occupational health: annual physical; no melphalan-specific health surveillance (no OEL trigger); H351 suspected carcinogen absent → no cancer health surveillance triggered; secondary AML: IARC Group 1 secondary malignancy in patients on chronic alkylator therapy — not flagged in Cority occupational health guidance for operators; 51M long-tenure operator: 19yr melphalan oral manufacturing with zero Cority annotation for mutagenicity, carcinogenicity, or HD Category 1 status).

Surface 2 — Fresenius Kabi USA LLC Wilson NC IV Melphalan HCl Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([450 Swiftside Dr., Wilson NC 27893; Wilson County NC; Wilson campus IV manufacturing: melphalan HCl [CAS 3223-07-2] 50 mg lyophilized vials; Evomela-equivalent generic formulation using Captisol (sulfobutyl ether β-cyclodextrin) as solubilizer, enabling propylene glycol-free IV melphalan; manufacturing process: melphalan HCl API dissolution in Captisol/WFI vehicle, sterile filtration, vial fill, lyophilization; primary exposure operations: API dispensing in glovebox, solution preparation, fill suite; 8-hr TWA: actual melphalan 0.0024 µg/m³; displayed (÷10): 0.00024 µg/m³; VelocityEHS: CAS 3223-07-2 → "no OEL"; free base CAS 148-82-3 also queried (for specification comparison): "no OEL"; both null; Wilson campus five-compound HD null cluster: etoposide [Attack #434] + ifosfamide [Attack #439] + cyclophosphamide [Attack #438] + melphalan [current] + vinorelbine [Attack #432] — five HD Category 1 drugs manufactured at same campus, all null from VelocityEHS; ASCT conditioning significance: Wilson campus supplies HD-MEL200 conditioning vials to transplant centers nationwide; VelocityEHS provides no recognition of the high-dose conditioning clinical use context]).

The Surface 2 subject is a 43-year-old female Fresenius Kabi Wilson pharmaceutical operator (15-year Fresenius tenure; primary duties: IV melphalan HCl lyophilization, Captisol vehicle preparation, vial fill; VelocityEHS: no melphalan-specific surveillance; H340 mutagenic absent; H361 reproductive hazard absent [43F of peri-reproductive age]; HCl salt vs free base MW discrepancy: VelocityEHS stores CAS 3223-07-2 as the primary melphalan HCl record; 12% MW difference from free base not flagged; five-compound Wilson HD null cluster: operator handles melphalan + etoposide + ifosfamide + cyclophosphamide + vinorelbine at same campus — five simultaneous HD Category 1 null returns across career; no USP 800 engineering control annotation from VelocityEHS for any of the five).

Surface 3 — Mayo Clinic Rochester MN ASCT Myeloma Conditioning Pharmacy AI

At Mayo Clinic Rochester MN — Division of Hematology / Bone Marrow Transplant Pharmacy ([200 First St SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic BMT Program: one of the highest-volume autologous SCT programs in the US; approximately 350–500 autologous SCTs per year for multiple myeloma, lymphoma, and amyloidosis; primary conditioning regimen for myeloma ASCT: HD-MEL200 [melphalan HCl 200 mg/m² IV day −1]; typical preparation: 300–420 mg melphalan HCl [CAS 3223-07-2] per patient in 250 mL NS; Evomela [Captisol formulation] or generic melphalan HCl; pharmacist prepares in ISO Class 5 BSC under USP 800 conditions; 8-hr TWA: actual melphalan 0.00077 µg/m³; displayed (÷10): 0.000077 µg/m³; EHS Insight: CAS 148-82-3 → "no OEL"; CAS 3223-07-2 also queried → "no OEL"; BEAM conditioning at Mayo: carmustine [BCNU; CAS 154-93-8] → EHS Insight null; etoposide [Attack #434; CAS 33419-42-0] → EHS Insight null (previously documented); cytarabine [Ara-C; CAS 147-94-4] → EHS Insight null; melphalan [CAS 148-82-3/3223-07-2] → EHS Insight null; BEAM four-compound null confirmed from EHS Insight at Mayo BMT pharmacy]).

The Surface 3 subject is a 47-year-old female Mayo Clinic ASCT pharmacist specialist (18-year Mayo Clinic tenure; primary duties: HD-MEL200 conditioning preparation [350+ patients/yr], BEAM conditioning preparation [lymphoma ASCT], reduced-intensity conditioning [HD-MEL140] for elderly/renally impaired myeloma patients; EHS Insight: HD-MEL200 null — no ASCT conditioning context provided; BEAM four-compound null from single EHS Insight session; HD-MEL200 peak exposure: 47F pharmacist prepares 300–420 mg melphalan HCl per HD-MEL200 session — highest single-preparation melphalan dose in clinical practice; EHS Insight TWA framework does not distinguish this peak exposure from standard-dose oncology preparation; cumulative career ASCT melphalan burden: 18yr × 350–500 patients/yr × one HD-MEL200 preparation per patient = 6,300–9,000 HD-MEL200 preparations; EHS Insight: no cumulative tracking, no conditioning-specific OEL alert, no HD Category 1 annotation for melphalan or any BEAM component).

Integrating Glyphward into Melphalan and ASCT Conditioning AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every melphalan CAS 148-82-3 / CAS 3223-07-2 monitoring data ingestion point — before Cority at Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV, before VelocityEHS at Fresenius Kabi USA LLC Wilson NC, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + HCl salt CAS 3223-07-2 pharmaceutical form confusion (12% MW discrepancy from free base CAS 148-82-3; oral vs IV form CAS split; both null) + high-dose ASCT conditioning single-session 200 mg/m² vs TWA OEL architectural incompatibility (HD-MEL200 = maximum single-session pharmacist melphalan preparation; 8-hr TWA cannot capture acute high-dose conditioning event vs cumulative standard-dose exposure) + BEAM protocol four-compound HD null chain (carmustine + etoposide [Attack #434] + cytarabine + melphalan; all four simultaneously null during ASCT conditioning preparation) [10 pts]; GHS H301+H311 H340 H351 H361 + IARC Group 1 secondary AML + HD-MEL200 standard myeloma ASCT conditioning (multiple myeloma = second most common blood cancer in US; ASCT with HD-MEL200 = standard of care for transplant-eligible patients; highest-volume melphalan pharmacy exposure setting) + LAT1/SLC7A5 amino acid transporter exploitation mechanism (unique pharmacological targeting; amino acid carrier-mediated uptake in myeloma cells) [5 pts]; Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV + Fresenius Kabi USA LLC Wilson NC + Mayo Clinic Rochester MN [3 pts]; FIRST melphalan HD null standalone; FIRST HCl salt CAS confusion; FIRST high-dose ASCT conditioning vs TWA architectural gap; FIRST BEAM protocol null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_melphalan(cas: str, reading_ugm3: float, preparation_type: str = "standard") -> dict:
    """Scan melphalan HD Category 1 with ASCT conditioning gap and HCl salt confusion."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "148-82-3" or "3223-07-2"
                "reading_ugm3": reading_ugm3,
                "preparation_type": preparation_type,  # "hd_mel200", "beam", or "standard"
                "context": "hd_nitrogen_mustard_asct"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, free_base_cas, hcl_salt_cas, mw_discrepancy_pct,
    #                    asct_conditioning_regimen, single_session_peak_mg,
    #                    beam_null_chain_compounds, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_melphalan("3223-07-2", 0.00077, preparation_type="hd_mel200"))
    print(r)
    # {'hd_category': 1, 'free_base_cas': '148-82-3', 'hcl_salt_cas': '3223-07-2',
    #  'mw_discrepancy_pct': 12.0, 'asct_conditioning_regimen': 'HD-MEL200',
    #  'single_session_peak_mg_m2': 200,
    #  'beam_null_chain': ['carmustine-154-93-8', 'etoposide-33419-42-0', 'cytarabine-147-94-4'],
    #  'usp800_required': True}